Exact Therapeutics AS
Research Exact Therapeutics AS (EXTX) on Bullrun: market cap NOK 77.52M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerEXTX
- ExchangeOL
- CountryNorway
- SectorHealthcare
- IndustryBiotechnology
- CurrencyNOK
- Market capNOK 77.52M
- Financial periodFY2025
- RevenueNOK 0
- Net income-NOK 86.97M
- Free cash flow-NOK 72.31M
Valuation Snapshot
latest market cap is NOK 77.52M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | NOK 0 | -NOK 86.97M | -NOK 72.31M | n/a | n/a | NOK 23.47M | NOK 434.91K | NOK 30.71M |
| FY2024 | NOK 0 | -NOK 52.33M | -NOK 82.05M | n/a | n/a | NOK 98.02M | NOK 646.72K | NOK 115.55M |
| FY2023 | NOK 0 | -NOK 48.33M | -NOK 47.39M | n/a | -1.51 | NOK 45.57M | NOK 1.20M | NOK 45.06M |
| FY2022 | NOK 0 | -NOK 40.10M | -NOK 34.10M | n/a | -1.34 | NOK 68.50M | NOK 1.69M | NOK 65.11M |
| FY2021 | n/a | n/a | n/a | n/a | -1.95 | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-29 | NOK 77.52M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 NOK.
About Exact Therapeutics AS
EXACT Therapeutics AS, a clinical stage biopharmaceutical company, develops a novel ultrasound-mediated technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT) in Norway. The ACT is an approach to ultrasound-mediated, targeted drug enhancement with the potential to amplify the clinical utility of a range of therapeutic agents across various applications, including oncology, neurological conditions, and gene therapy.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Exact Therapeutics AS's market cap?
Exact Therapeutics AS's market capitalization is NOK 77.52M.
What does Exact Therapeutics AS do?
EXACT Therapeutics AS, a clinical stage biopharmaceutical company, develops a novel ultrasound-mediated technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT) in Norway. The ACT is an approach to ultrasound-mediated, targeted drug enhancement with the potential to amplify the clinical utility of a range of therapeutic agents across various applications, including oncology, neurological conditions, and gene therapy.